The webinar will feature a presentation from Key Opinion Leader (KOL) Oskar Hansson MD, PhD, of Skåne University Hospital. During his presentation, Dr. Hansson will discuss the importance of biomarkers and precision medicine in Alzheimer’s disease and α-synucleinopathies (e.g. multiple system atrophy), as well as first-in-human study data on AC Immune’s α-synuclein positron emission tomography (PET) tracer, which will be announced on March 18, 2022 at the upcoming AD/PD^TM conference.

Additionally, members of the AC Immune management team will provide an overview of the Company’s corporate strategy and discuss clinical development plans for its α-synuclein PET tracer and ACI-7104, a clinically-validated α-synuclein vaccine being developed as a treatment for Parkinson’s disease.

A live question and answer session will follow the formal presentation.